DMLA

<!-- Name:DistributionId Value:1000797398 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4535 -->…

<!-- Name:DistributionId Value:1000795200 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4535 -->…

<!-- Name:DistributionId Value:1000783170 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4535 -->…

<!-- Name:DistributionId Value:1000782661 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4535 -->…

<!-- Name:DistributionId Value:1000782444 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4535 -->…

<!-- Name:DistributionId Value:1000779429 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4535 -->…

Pixium Vision convenes an Extraordinary General Meeting of Shareholders on February 15, 2023 Paris, France, January 20, 2023 – 19:00 CET– Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops…

Pixium Vision announces peer-reviewed publications demonstrating the potential of the Next Generation PRIMA implant to restore vision at five times higher resolution than current implant New implants leverage existing PRIMA design with…

Pixium Vision welcomes judgment by Paris Commercial Court against Second Sight Medical Products Court finds Second Sight Medical Products breached 2021 contractual obligations to Pixium VisionCourt orders Second Sight Medical Products to…

Pixium Vision announces completion of implantations in the European pivotal trial PRIMAvera and confirms target read-out around the end of 2023 and regulatory submission in Europe in H1 2024 38 patients have been implanted with Prima…